Pharmaceutical Research Acute Heart Failure Therapeutics Market 2026 | Page 3

REPORT DESCRIPTION
Acute Heart Failure (AHF) Therapeutics Market Drivers
The global acute heart failure therapeutics market is expected to witness significant growth
due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and
Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on
the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce
the risk of cardiovascular death and heart failure hospitalization.
Request for Report Sample:
https://www.coherentmarketinsights.com/insight/request-sample/1910
Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another
factor driving growth of acute heart failure therapeutics market. For instance, in March
2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which
now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’
acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical
development phase. CXL-1427 is indicated to use as an intravenous treatment for acute
decompensated heart failure (ADHF). Successful completion and further launch of Bristol-
Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF)
therapeutics market growth during the forecast period.
© Coherent market Insights. All Rights Reserved